Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Carisma Therapeutics (CARM)
NASDAQ:CARM
RESEARCH TOOLSreports
Holding CARM?
Track your performance easily
CARM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.38 - $3.16
Previous Close$0.42
Volume304.44K
Average Volume (3M)211.16K
Market Cap
$18.43M
Enterprise Value-$5.13M
Total Cash (Recent Filing)$26.88M
Total Debt (Recent Filing)$3.32M
Price to Earnings (P/E)―
Beta2.64
Next Earnings
Apr 08, 2025EPS Estimate
-$0.18Last Dividend Ex-Date
Mar 08, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding41,750,109
10 Day Avg. Volume534,460
30 Day Avg. Volume211,156
Standard Deviation0.29
R-Squared0.07
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)-1.55
Price to Sales (P/S)0.91
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.02
Enterprise Value/Gross Profit-0.05
Enterprise Value/Ebitda0.09
Forecast
1Y Price Target
$4.57Price Target Upside993.56% Upside
Rating ConsensusHold
Number of Analyst Covering5
Carisma Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company expects its current cash runway to last through the third quarter of 2025, providing a degree of financial stability.
Innovative Platform And ApproachThe combination of Carisma's CAR expertise with Moderna's lipid nanoparticle platform to induce CAR expression in vivo editing will allow for an off-the-shelf approach that will reduce costs and substantially expand the access to Carisma's technology.
Partnership And ExpansionThe expansion of Carisma's partnership with Moderna to include autoimmune programs in addition to oncology work is viewed as a positive signal.
Bears Say
Analyst DowngradeThe rating for Carisma has been downgraded from Buy to Neutral due to a lack of near-term catalysts and a financing overhang.
Program DiscontinuationCarisma Therapeutics announced the discontinuation of their lead HER-2 monocyte program CT-0525 due to lack of strong enrollment and evolving clinical landscape in the treatment of HER2 tumors.
Workforce ReductionThe company's workforce will be reduced by 34% with associated expenses, indicating a significant reorganization effort.
---
Ownership Overview
1.43%
Insiders
4.33% Mutual Funds
4.60% Other Institutional Investors
86.07% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CARM FAQ
What was Carisma Therapeutics’s price range in the past 12 months?
Carisma Therapeutics lowest stock price was $0.38 and its highest was $3.16 in the past 12 months.
What is Carisma Therapeutics’s market cap?
Currently, no data Available
When is Carisma Therapeutics’s upcoming earnings report date?
Carisma Therapeutics’s upcoming earnings report date is Apr 08, 2025 which is in 107 days.
How were Carisma Therapeutics’s earnings last quarter?
Carisma Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.315 by $0.005.
Is Carisma Therapeutics overvalued?
According to Wall Street analysts Carisma Therapeutics’s price is currently Undervalued.
Does Carisma Therapeutics pay dividends?
Carisma Therapeutics pays a Notavailable dividend of $0.361 which represents an annual dividend yield of N/A. See more information on Carisma Therapeutics dividends here
What is Carisma Therapeutics’s EPS estimate?
Carisma Therapeutics’s EPS estimate is -$0.18.
How many shares outstanding does Carisma Therapeutics have?
Carisma Therapeutics has 41,750,110 shares outstanding.
What happened to Carisma Therapeutics’s price movement after its last earnings report?
Carisma Therapeutics reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.315. Following the earnings report the stock price went down -7.207%.
Which hedge fund is a major shareholder of Carisma Therapeutics?
Among the largest hedge funds holding Carisma Therapeutics’s share is Wexford Capital LP. It holds Carisma Therapeutics’s shares valued at 34K.
---
Carisma Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.57 (993.56% Upside)
$4.57 (993.56% Upside)
Blogger Sentiment
Bullish
CARM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 15.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.41%
12-Months-Change
Fundamentals
Return on Equity
-362.79%
Trailing 12-Months
Asset Growth
-60.61%
Trailing 12-Months
Company Description
Carisma Therapeutics
Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.
---
CARM Stock 12 Month Forecast
Average Price Target
$4.57
▲(993.56% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Corvus Pharmaceuticals
―
Fate Therapeutics
―
Kura Oncology
―
Best Analysts Covering CARM
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-71.43%
reiterated a buy rating 5 months ago
Copying Naureen Quibria's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -71.43% per trade.
---